Share on StockTwits

C.R. Bard (NYSE:BCR) will be issuing its quarterly earnings data on Thursday, January 30th. Persons interested in participating in the company’s earnings conference call can do so using this link.

Shares of C.R. Bard (NYSE:BCR) opened at 130.75 on Wednesday. C.R. Bard has a 52 week low of $97.14 and a 52 week high of $141.02. The stock has a 50-day moving average of $133.5 and a 200-day moving average of $125.5. The company has a market cap of $10.184 billion and a P/E ratio of 71.67.

BCR has been the subject of a number of recent research reports. Analysts at Barclays raised their price target on shares of C.R. Bard from $140.00 to $150.00 in a research note to investors on Thursday, January 9th. They now have an “overweight” rating on the stock. On the ratings front, analysts at Atlantic Securities upgraded shares of C.R. Bard from a “neutral” rating to an “overweight” rating in a research note to investors on Wednesday, January 8th. They now have a $148.00 price target on the stock, up previously from $118.00. Finally, analysts at JPMorgan Chase & Co. downgraded shares of C.R. Bard from an “overweight” rating to a “neutral” rating in a research note to investors on Monday, January 6th. They now have a $142.00 price target on the stock. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $131.31.

In other C.R. Bard news, COO John Weiland sold 81,500 shares of C.R. Bard stock on the open market in a transaction dated Thursday, January 16th. The shares were sold at an average price of $136.13, for a total transaction of $11,094,595.00. Following the sale, the chief operating officer now directly owns 133,483 shares in the company, valued at approximately $18,171,041. The transaction was disclosed in a filing with the SEC, which is available at this link.

C. R. Bard, Inc (NYSE:BCR) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.